Atlas Trials

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Clinical trial NCT05891119 · COMPLETED

Trial details

NCT number
NCT05891119
Sponsor
Amgen
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Atopic Dermatitis
Start date
2023-06-03
Primary completion
2024-08-28
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.